A Phase 1 interventional study of HMPL-523 Acetate Tablets (Test Formulation) and HMPL-523 Acetate Tablets (Reference Formulation) in Healthy, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Hutchmed · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after administration at the same molar dose. Formulations with bioequivalence are considered to act comparably in vivo, i.e., similar in terms of safety and efficacy.
This study aims to evaluate the pharmacokinetic (PK) profile and bioequivalence of the original and modified formulations of HMPL-523 acetate tablets in healthy participants to bridge the safety and efficacy of the modified formulation of HMPL 523 acetate tablets in humans.
This study adopts a single-center, randomized, open-label, single-dose, four-cycle, fully replicate clinical trial design to evaluate the PK profile and bioequivalence of two different formulations of HMPL-523 acetate tablets in healthy participants. In this study, a total of 54 Chinese healthy participants are planned to be enrolled and randomly assigned to 2 dosing sequence groups (TRTR, and RTRT) in a 1:1 ratio, and administered once per cycle, with a washout period of at least 7 days, where T is the test formulation (the modified formulation) and R is the reference formulation (the original formulation).
The study will be divided into 3 periods: screening/baseline period, dosing period (four cycles), and follow-up period. The entire study from the screening period to the follow-up period is expected to last approximately 2 months.
Screening Period/Baseline Period The trial participants will sign a written informed consent form (ICF) on a voluntary basis prior to screening. Screening period/baseline period assessment will be completed within 14 days prior to the first dose. At screening/baseline, demographic data, medical history, medication history, allergy history, blood donation history, and participation in clinical trials should be collected, and physical examination, vital sign measurements, alcohol breath test, urine drug abuse screening, 12-lead ECG, infection markers [including hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, and Treponema pallidum antibody], laboratory tests (including hematology, blood chemistry, coagulation test, urinalysis), pregnancy test (female) and chest X-ray (frontal and lateral) examination will be performed. Only serious adverse events (SAEs) will be collected at screening/baseline.
Dosing Period (4 cycles) Eligible participants upon preliminary screening will be required to be admitted to the site 3 days before the first dose (i.e., 3 days prior to the initiation of the first cycle of medication). On the day of admission, vital sign measurements and inquiry about recent diet and medication, and pregnancy test (females only) will be performed to further verify the inclusion and exclusion criteria. According to the randomization scheme, eligible participants upon screening will be assigned a random number and randomly assigned to different dosing sequences (TRTR or RTRT). Based on the randomized dosing regimen, participants in different groups will take the test formulation or the reference formulation respectively after intake of breakfast (standard meal) on the first day of each cycle. The dosing regimen is detailed in the table below.
Crossover dosing regimen Group Number of participants Intake of standard meal breakfast Cycle 1 Cycle 2 Cycle 3 Cycle 4 TRTR 27 T R T R RTRT 27 R T R T
Method of administration:
Participants will fast for at least 10 hours before a standard meal on the first day of each cycle, start having a standard meal 30 minutes before dosing, and finish the meal within 25 minutes. After the meal, participants will have blank blood samples collected, and take the medication with about 240 mL of water on time 30 minutes after the meal. Except for the above-mentioned water for medication, participants are deprived of water is prohibited from 1 hour prior to the medication to 1 hour after the medication, and deprived of food within 4 hours after the medication. During hospitalization, the diet of the participants will be provided by the site.
The dosing period consists of four cycles, and the scheduled PK blood sampling time points for each participant in each cycle is as follows: within 0.5 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, 72 hours post-dose, with a total of 18 collections (see Table 2 for details), and about 3 mL of venous blood collected each time.
After the participants are admitted to the clinical study ward, the vital sign measurements will be performed 1 day pre-dose in each cycle and 3±1 hours post-dose on the first day of each cycle. In addition, vital sign measurements, blood chemistry, and hematology will be performed on the Day 4 of the each of the first three cycles. On Cycle 4 Day 4, the participants will be discharged after vital sign measurements, physical examination, laboratory tests, and 12-lead ECG examination are completed.
Follow-up Period Participants will be followed up to Day 12±2 after the last dose (the day of the last dose is defined as Day 1 of follow-up period). The investigator will collect all AEs and concomitant medications/therapies from the participants during this period through telephone calls (or other means such as text messages). If there are AEs ongoing at follow-up, follow-up will continue until return to normal level, abnormal, not clinically significant, baseline level, stable or lost to follow-up, or refusal to visit, etc.,
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Trial participants must meet all of the following criteria for enrollment:
Exclusion Criteria:
Study participants must be excluded from this study if one of the following conditions is met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Total 54 Chinese healthy participants are planned to be enrolled and randomly assigned to 2 dosing sequence groups (TRTR, and RTRT) in a 1:1 ratio and administered once per cycle, with a washout period of at least 7 days, where T is the test formulation (the modified formulation) and R is the reference formulation (the original formulation). the dose is 300mg for each cycle, and there were 4 cycles for each participant.
Drug: HMPL-523 Acetate Tablets (Test Formulation) · Drug: HMPL-523 Acetate Tablets (Reference Formulation)
Total 54 Chinese healthy participants are planned to be enrolled and randomly assigned to 2 dosing sequence groups (TRTR, and RTRT) in a 1:1 ratio and administered once per cycle, with a washout period of at least 7 days, where T is the test formulation (the modified formulation) and R is the reference formulation (the original formulation). the dose is 300mg for each cycle, and there were 4 cycles for each participant.
Drug: HMPL-523 Acetate Tablets (Test Formulation) · Drug: HMPL-523 Acetate Tablets (Reference Formulation)
The trial participants were administered the drug on the first day of each cycle. dose 300mg
The trial participants were administered the drug on the first day of each cycle. dose 300mg
PK parameters
area under the plasma concentration-time curve from 0 to the time point t when the last concentration can be accurately measured (AUC0-t)
Time frame: up to two months
PK parameters
area under the plasma concentration-time curve from 0 to infinity (AUC0-∞)
Time frame: up to two months
PK parameters
maximum concentration (Cmax)
Time frame: up to two months
PK parameters
time to maximum concentration (Tmax)
Time frame: up to two months
PK parameters
terminal elimination half-life (t1/2)
Time frame: up to two months
The bioequivalence of two different drug product formulations of HMPL 523 acetate tablets
It will be evaluated based on the area under the plasma concentration-time curve (AUC) and Cmax.
Time frame: up to two months
To compare the relative bioavailability of two different drug product formulations of 300 mg (100 mg/tablet × 3) HMPL-523 acetate tablets
Relative bioavailability (ratio of AUC of two different HMPL-523 acetate tablets)
Time frame: up to two months
Adverse events (AEs)
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: up to two months
Laboratory tests
Number of participants with abnormal laboratory tests results
Time frame: up to two months
Ran from Oct 2025 to primary completion in Nov 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.